Secoya Technologies

Secoya Technologies is a Belgian medical technology company that positions itself as a partner specialised in pharmaceutical precision processes. Combining deep scientific knowledge with proprietary technologies and engineering capabilities, the company supports pharmaceutical and biotech companies from early research through process development to technical implementation at production scale. Its stated core principle is applied to crystallization, emulsification and pervaporation, and its About page additionally lists encapsulation and continuous chemical synthesis, giving four process technologies in total. Rather than selling a single commodity machine, Secoya designs tailored process solutions and equipment through close collaboration with clients. It bridges scientific understanding with engineering execution to help accelerate the development of robust and innovative pharmaceutical processes, and it reports a track record with key partners in the pharmaceutical industry. Its core competencies span process and scientific expertise — organic and flow chemistry, materials science, microfluidics, formulation development and manufacturing processes — and engineering and equipment design, including custom process design, mechanical engineering, equipment development, adaptable ready-to-use systems, and on-site installation and qualification. The company offers a structured suite of advanced services built around integrating microfluidic technologies for precise control and efficiency. These begin with a short, fast, low-cost assessment study to determine feasibility, benefits and technical requirements for a specific compound, formulation or challenge; continue with a hands-on feasibility study screening toward the target; move to data-driven optimization of the optimal conditions; then scale to full production mode with long runs on modular, reproducible equipment; and finish with on-site installation and qualification, technology transfer, operator training, maintenance and after-sales service. Secoya's equipment line includes the SCT-PILOT unit, described as the perfect cross-over for upscaling viability studies. It allows full exploration of the design space of a crystallization process, performing controlled long-term runs on a single reactor under the same experimental conditions as the SCT-LAB unit, while sharing the identical pump and fluidic setup as the larger SCT-ICE unit. With cGMP execution and automated, compliant software it can also allow production of clinical batches, and it can be equipped with different vessel volumes and connected to various slurry-treatment options. The underlying crystallization technology is based on precise control of spontaneous nucleation using millifluidic tubular reactors upon cooling with different antisolvent addition possibilities, enabling crystallization of molecules in a single process step and avoiding difficult work-up associated with conventional batch systems. The company's three key principles are intensification, smart scale-up and — as presented on its site — a third principle tied to full control over daily desired production rates and adaptability. Intensification is framed as going beyond yield and environmental footprint to include control over production rates and their impact on cost of goods. Smart scale-up keeps individual output control per single, highly intensified reactor possible, matching even the smallest requirements. The team listed on the About page includes CEO Bertrand Loriers, Technology Lead for Emulsification & Droplet Generation Adrien Dewandre, Technology Lead for Pervaporation & Process Intensification Jean Septavaux, Technology Lead for Crystallization Bart Rimez, and co-founders Benoit Scheid and Alex Vandekerckhove. Secoya is a private Belgian company and is described by Wikidata as a Belgian medical technology company.

Secoya Technologies is a Belgian medical technology company that has built its business around pharmaceutical precision processes. Public information about its founding date is not provided in the available evidence, but the company presents itself as a partner specialised in pharmaceutical precision processes, combining deep scientific knowledge with proprietary technologies and engineering capabilities to support pharmaceutical and biotech companies from early research to process development and technical implementation at production scale. The company's technical foundation rests on proprietary process technologies. Its homepage highlights crystallization, emulsification and pervaporation as core technologies, while its About page describes expertise and equipment across four process technologies: crystallization, encapsulation, pervaporation and continuous chemical synthesis. This technology set is delivered through equipment and services rather than as standalone chemistry, reflecting Secoya's model of designing tailored process solutions and equipment through close collaboration with clients. Secoya's crystallization technology is based on precise control of spontaneous nucleation through the use of millifluidic tubular reactors upon cooling, with different antisolvent addition possibilities. Using such capillaries, parameters influencing nucleation are optimized and controlled, which the company says enables crystallization of molecules in a single process step and avoids difficult work-up when performed with conventional batch systems. This technology is embodied in a family of units: the SCT-LAB, the SCT-PILOT and the SCT-ICE. The SCT-PILOT is positioned as the cross-over instrument for upscaling viability studies, sharing the identical pump and fluidic setup as the larger SCT-ICE unit and the same combination of inserts and reactors as the SCT-LAB unit. With cGMP execution and automated, compliant software, the SCT-PILOT can also allow production of clinical batches. Alongside equipment, Secoya offers a structured service pathway. An assessment study provides a short, fast, low-cost structured evaluation to determine feasibility, benefits and technical requirements for a specific compound, formulation or challenge. A feasibility study provides a first screening toward the target through hands-on technical evaluation, answering questions about efficiency, reproducibility and scalability. An optimization study then uses a data-driven approach to define the best possible set of parameters and prepare for scale-up. Scaling to full production mode involves long runs on modular and reproducible equipment architecture, with runs on single and multiple channels and a cost evaluation prior to investment. Finally, on-site installation and qualification covers technology transfer, operator training, on-site assistance, maintenance and after-sales service. The company articulates three key principles guiding its methodology. Intensification is described as going beyond increasing yield and reducing environmental footprint to include full control over daily desired production rates and the ability to adapt them easily, with a major impact on cost of goods. Smart scale-up keeps individual output control per single, highly intensified reactor possible, matching even the smallest requirements. The third principle, as presented on the homepage, relates to control and adaptability in production. Secoya's leadership and technical team is publicly listed on its About page. Bertrand Loriers serves as CEO. Technology leads cover the company's main technology areas: Adrien Dewandre for emulsification and droplet generation, Jean Septavaux for pervaporation and process intensification, and Bart Rimez for crystallization. Benoit Scheid and Alex Vandekerckhove are listed as co-founders. The company reports a track record with key partners in the pharmaceutical industry and operates as a private Belgian company, described by Wikidata as a Belgian medical technology company.

A specialised pharmaceutical precision-process partner combining scientific expertise with proprietary technologies and engineering to deliver tailored process solutions and equipment from laboratory to commercial production scale.

• SCT-PILOT

  A crystallization unit that allows full exploration of the design space of a crystallization process, performing controlled long-term runs on a single reactor under the same experimental conditions as the SCT-LAB unit. It shares the identical pump and fluidic setup as the SCT-ICE unit and the same combination of inserts and reactors as the SCT-LAB unit, making it the cross-over instrument for upscaling studies. With cGMP execution and automated, compliant software it can also allow production of clinical batches, and it can be equipped with different vessel volumes and connected to various slurry-treatment options.

• SCT-LAB

  A laboratory-scale crystallization unit referenced as sharing the same combination of inserts and reactors as the SCT-PILOT unit.

• SCT-ICE

  A larger crystallization unit referenced as sharing the identical pump and fluidic setup as the SCT-PILOT unit.

1. 1Home - Secoya Technologiessecoya-tech.com
2. 2About Secoya - high quality (bio-)pharmaceutical productssecoya-tech.com
3. 3Services - Secoyasecoya-tech.com
4. 4SCT-Pilot - Secoya The perfect cross-over for upscaling viability studiessecoya-tech.com
5. 5Secoyawikidata.org